权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Engineering iPSC-Derived Skeletal Muscle and Cells for Transplantation

工程化 iPSC 衍生的骨骼肌和细胞用于移植

基本信息

批准号：
9164844
负责人：
ATSUSHI ASAKURA
金额：
$ 20.14万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9164844
关键词：
Accidents Aging Animal Model Animals Autologous Cell Nucleus Cell Transplantation Cell Transplants Cells Cessation of life Characteristics Chimera organism Chronic Chronic Disease Complement Defect Disease Duchenne muscular dystrophy Embryo Embryonic Development Engineering Engraftment Ethical Issues Fetus First Pregnancy Trimester Generations Goals Human Human Characteristics Human body Immune Injection of therapeutic agent Injury Intraperitoneal Injections Limb structure Locomotion Metabolism Methods Molecular Profiling Mus Muscle Muscle Development Muscle Fibers Muscle Weakness Muscular Atrophy Mutant Strains Mice Mutation Myopathy Names Natural regeneration Operative Surgical Procedures Patients Perinatal Play Production Proliferating Recovery Regenerative Medicine Reporting Respiratory Muscles Risk Role Route Skeletal Muscle Source Stem cell transplant Stem cells Testing Therapeutic Thermogenesis Tissues Transplantation abstracting age related blastocyst cell motility clinically significant in utero in vivo individual patient induced pluripotent stem cell innovation intraperitoneal knockout gene muscle transplantation mutant myogenesis organ growth organ regeneration precursor cell regenerative repaired response sarcopenia satellite cell scale up skeletal stem cell population stem cell technology study characteristics

项目摘要

Abstract Chronic muscle diseases including Duchenne muscular dystrophy (DMD) and aging-related sarcopenia result in muscle weakness, loss of independence, and increased risk of death. In addition, traumatic muscle injury and loss due to accidents, surgery, and wartime injuries needs prolonged recovery. Skeletal muscle is a highly regenerative tissue in which satellite cells, a stem cell population for skeletal muscle, play essential roles in creating and repairing skeletal muscle. However, this potential ultimately fails with disease and aging. Autologous satellite cell transplantation is a potential approach to create and repair skeletal muscle fibers, but satellite cells are rare (a few % of all muscle nuclei) and often difficult to isolate. Patient-derived induced pluripotent stem cells (iPSCs) are the ideal cell source to obtain an unlimited number of myogenic cells that escape immune rejection after engraftment. However, efficient myogenic differentiation and the scale-up of myogenic differentiation remain elusive and must be developed further in order to generate effective cellular therapies. A key to the generation of human myogenic cells and skeletal muscle in a host animal is the selective knockout of genes in the blastocyst that are critical for organ development. Therefore, in this proposal, (1) we will determine to which extent mouse iPSC-derived limb skeletal muscle will be generated after injection of mouse iPSCs into Pax3 mutant mouse blastocysts, creating a niche in which stem cells can occupy and form skeletal muscle in the limb. This approach will provide evidence for the creation of entire skeletal muscle by mouse iPSCs in vivo. In addition, (2) we will generate a humanized skeletal muscle using Pax3 mutant mouse embryos via in utero injection of human iPSCs in combination with Pax3 mutant embryos and iPSCs. This concerted approach will help us to create iPSC-derived skeletal muscle and myogenic cells in vivo that can be transplanted into patients for a definitive cure of myopathic diseases and muscle injuries. In addition, the humanized skeletal muscle in mice will serve as an animal model to study the characteristics and regeneration characteristics of the human skeletal muscle diseases and responses to pharmacological agents and to provide a proof of concept for generating patient-derived cell and tissue sources for autologous muscle transplantation. .

摘要